• Molecular NameFulvestrant
  • Synonymfulvestrant; ICI 182,780
  • Weight606.781
  • Drugbank_IDDB00947
  • ACS_NO129453-61-8
  • Show 3D model
  • LogP (experiment)7.848
  • LogP (predicted, AB/LogP v2.0)8.68
  • pkaN/A
  • LogD (pH=7, predicted)8.68
  • Solubility (experiment)Very low
  • LogS (predicted, ACD/Labs)(ph=7)-6.81
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds15
  • TPSA76.74
  • StatusFDA approved
  • AdministrationIntramuscular injection
  • PharmacologyA drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)3.0~5.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmEliminated by conjugation (sulfate and glucuronide) and CYP3A4-mediated oxidation. Data reported for men and women; no significant gender differences.
  • Half life14~19 h (Elimination t1/2 following IV administration. The apparent t?? following IM dosing is approximately 40 days due to very prolonged absorption)
  • ExcretionN/A
  • Urinary Excretion<1
  • Clerance9.3~14.3 ml/min/kg
  • ToxicityThe most commonly reported adverse effects occured in patients treated with Faslodex were gastrointestinal symptoms (including nausea, vomiting, constipation, diarrhea and abdominal pain), headache, back pain, vasodilatation (hot flushes), and pharyngitis.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A